{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:11:31Z","timestamp":1794744691492,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-na\u00efve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS \u2265\u202f8, PSA \u2265\u202f20\u202fng\/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS \u2265\u202f8; PSA &gt;\u202f0.7\u202fng\/ml). If PSMA-PET\/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.<\/jats:p>","DOI":"10.1007\/s00066-023-02193-4","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:34:32Z","timestamp":1706204072000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prostate cancer and elective nodal radiation therapy for cN0 and pN0\u2014a\u00a0never ending story?"],"prefix":"10.1007","volume":"200","author":[{"given":"S. A.","family":"Koerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"H\u00f6cht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.-S.","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Niehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K. B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2193_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1748-717X-7-86","volume":"7","author":"L Caravatta","year":"2012","unstructured":"Caravatta\u00a0L, Sallustio\u00a0G, Pacelli\u00a0F et\u00a0al (2012) Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 7:86","journal-title":"Radiat Oncol"},{"issue":"5","key":"2193_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jrr\/rry055","volume":"59","author":"YJ Cheng","year":"2018","unstructured":"Cheng\u00a0YJ, Jing\u00a0SW, Zhu\u00a0LL et\u00a0al (2018) Comparison of elective nodal irradiation and involved-field irradiation in esophageal squamous cell carcinoma: a\u00a0meta-analysis. J\u00a0Radiat Res 59(5):604\u2013615","journal-title":"J Radiat Res"},{"key":"2193_CR3","doi-asserted-by":"publisher","first-page":"1067321","DOI":"10.3389\/fonc.2022.1067321","volume":"12","author":"EA Mensour","year":"2022","unstructured":"Mensour\u00a0EA, Alam\u00a0S, Mawani\u00a0S et\u00a0al (2022) What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A\u00a0review of ongoing clinical trials. Front Oncol 12:1067321","journal-title":"Front Oncol"},{"issue":"1","key":"2193_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijrobp.2021.07.1698","volume":"112","author":"JA Miller","year":"2022","unstructured":"Miller\u00a0JA, Toesca\u00a0DAS, Baclay\u00a0JRM et\u00a0al (2022) Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation. Int J Radiat Oncol Biol Phys 112(1):131\u2013142","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2193_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00066-021-01871-5","volume":"198","author":"S Cozzi","year":"2022","unstructured":"Cozzi\u00a0S, Botti\u00a0A, Timon\u00a0G et\u00a0al (2022) Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for iymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol 198(8):700\u2013709","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"2193_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet\u00a0N, van den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262","journal-title":"Eur Urol"},{"issue":"24","key":"2193_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla\u00a0M, de Reijke\u00a0TM, Van Tienhoven\u00a0G et\u00a0al (2009) Duration of androgen suppression in the treatment of prostate cancer. N\u00a0Eng J Med 360(24):2516\u20132527","journal-title":"N Eng J Med"},{"issue":"2","key":"2193_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton\u00a0CAF, Lin\u00a0X, Hanks\u00a0GE et\u00a0al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update if NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98(2):296\u2013303","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2193_CR9","doi-asserted-by":"crossref","unstructured":"Zapatero A, Guerrero A, Maldonado X et\u00a0al High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART01\/05 GICOR): a\u00a0randomised, controlled, phase\u00a03\u00a0trial. Lancet 16(3):320\u2013327","DOI":"10.1016\/S1470-2045(15)70045-8"},{"issue":"4","key":"2193_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","volume":"106","author":"D Joseph","year":"2020","unstructured":"Joseph\u00a0D, Denham\u00a0JW, Steigler\u00a0A et\u00a0al (2020) Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial. Int J Radiat Oncol Biol Phys 106(4):693\u2013702","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2193_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0360-3016(86)90349-4","volume":"12","author":"MV Pilepich","year":"1986","unstructured":"Pilepich\u00a0MV, Krall\u00a0JM, Johnson\u00a0RJ et\u00a0al (1986) Extended field (paraaortic) irradiation in carcinoma of the prostate\u2014analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12(3):345\u2013351","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2193_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/0360-3016(88)90225-8","volume":"15","author":"SO Asbell","year":"1988","unstructured":"Asbell\u00a0SO, Krall\u00a0JM, Pilepich\u00a0MV et\u00a0al (1988) Elective pelvic irradiation in stage A2,B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307\u20131316","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2193_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","volume":"69","author":"CA Lawton","year":"2007","unstructured":"Lawton\u00a0CA, DeSilvio\u00a0M, Roach\u00a0M 3rd (2007) and al.: An updated of the phase\u00a0III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646\u2013655","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"2193_CR14","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","volume":"25","author":"P Pommier","year":"2007","unstructured":"Pommier\u00a0P, Chabaud\u00a0S, Lagrange\u00a0JL et\u00a0al (2007) Is there a\u00a0role for pelvic irradiation in localized prostate cancer? Preliminary results of GETUG-01. J\u00a0Clin Oncol 25(34):5366\u20135373","journal-title":"J Clin Oncol"},{"key":"2193_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","volume":"96","author":"P Pommier","year":"2016","unstructured":"Pommier\u00a0P, Chabaud\u00a0S, Lagrange\u00a0JL et\u00a0al (2016) Is there a\u00a0role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96:759\u2013769","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2193_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","volume":"19","author":"M Roach","year":"2018","unstructured":"Roach\u00a0M, Moughan\u00a0J, Lawton\u00a0CAF et\u00a0al (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localized prostate cancer (NRG\/RTOG 9413): long-term results of a\u00a0randomized, phase\u00a03\u00a0trial. Lancet 19(11):1504\u20131515","journal-title":"Lancet"},{"key":"2193_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","volume":"103","author":"D Dearneley","year":"2019","unstructured":"Dearneley\u00a0D, Griffin\u00a0CL, Lewis\u00a0R et\u00a0al (2019) Toxicity and patient-reported outcomes of a\u00a0phase\u00a02 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localized prostate cancer (PIVOTAL). Int J Radiat Oncol Biol Phys 103:605\u2013617","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2193_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy\u00a0V, Maitre\u00a0P, Kannan\u00a0S et\u00a0al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase\u00a0III randomized controlled trial. J\u00a0Clin Oncol 39(11):1234\u20131242","journal-title":"J Clin Oncol"},{"key":"2193_CR19","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","volume":"35","author":"W Xie","year":"2017","unstructured":"Xie\u00a0W, Regan\u00a0MM, Buyse\u00a0MM et\u00a0al (2017) Metastasis-free survival is a\u00a0strong surrogate of overall survival in localized prostate cancer. J\u00a0Clin Oncol 35:3097\u20133104","journal-title":"J Clin Oncol"},{"key":"2193_CR20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1186\/s12885-020-07490-0","volume":"20","author":"LC Mendez","year":"2020","unstructured":"Mendez\u00a0LC, Arifin\u00a0AJ, Bauman\u00a0GS et\u00a0al (2020) Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer 20:978","journal-title":"BMC Cancer"},{"key":"2193_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2019.03.022","volume":"77","author":"KA Sandler","year":"2020","unstructured":"Sandler\u00a0KA, Cook\u00a0RR, Ciezki\u00a0JP et\u00a0al (2020) Prostate-only versus whole-pelvis radiation with or without a\u00a0brachytherapy boost for Gleason grade group\u00a05 prostate cancer: a\u00a0retrospective analysis. Eur Urol 77:3\u201310","journal-title":"Eur Urol"},{"key":"2193_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ijrobp.2019.09.044","volume":"106","author":"H Tharmalingam","year":"2020","unstructured":"Tharmalingam\u00a0H, Tsang\u00a0Y, Choudhury\u00a0A et\u00a0al (2020) External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 106:525\u2013533","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2193_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","volume":"71","author":"DE Spratt","year":"2017","unstructured":"Spratt\u00a0DE, Vargas\u00a0HA, Zumsteg\u00a0ZS et\u00a0al (2017) Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol 71:37\u201343","journal-title":"Eur Urol"},{"key":"2193_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS, Lawrentschuk\u00a0N, Francis\u00a0RJ et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a\u00a0prospective, randomized, multicenter study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"2193_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.05.014","author":"T Niazi","year":"2023","unstructured":"Niazi\u00a0T, Nabid\u00a0A, Malagon\u00a0T et\u00a0al (2023) Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the prostate cancer study\u20115, a\u00a0groupe de radio-oncologie g\u00e9nito-urinaire de quebec led phase\u00a03\u00a0trial. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.05.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2193_CR26","volume-title":"2022 ASTRO Annual Meeting","author":"T Niazi","year":"2022","unstructured":"Niazi\u00a0T, Nabid\u00a0A, Malagon\u00a0T et\u00a0al (2022) Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer. In: 2022 ASTRO Annual Meeting, vol 4 (Presented October\u00a023)"},{"key":"2193_CR27","first-page":"22","volume":"25","author":"I Syndikus","year":"2020","unstructured":"Syndikus\u00a0I, Cruickshank\u00a0C, Staffurth\u00a0J et\u00a0al (2020) PIVOTALboost: a\u00a0phase\u00a0III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018). Clin Transl Radiat Oncol 25:22\u201328","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"2193_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope\u00a0TA, Eiber\u00a0M, Armstrong\u00a0WR et\u00a0al (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a\u00a0multicenter prospective phase\u00a03 imaging trial. JAMA Oncol 7(11):1635\u20131642","journal-title":"JAMA Oncol"},{"issue":"5","key":"2193_CR29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ijrobp.2017.07.041","volume":"99","author":"M Reis Ferreira","year":"2017","unstructured":"Reis Ferreira\u00a0M, Khan\u00a0A, Thomas\u00a0K et\u00a0al (2017) Phase\u00a01\/2 dose-escalation study of the use of intensity modulated radiation therapy to treat the prostate and pelvic nodes in patients with prostate cancer. Int J Radiat Oncol Biol Phys 99(5):1234\u20131242","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"35","key":"2193_CR30","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","volume":"32","author":"F Abdollah","year":"2014","unstructured":"Abdollah\u00a0F, Karnes\u00a0RJ, Suardi\u00a0N et\u00a0al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J\u00a0Clin Oncol 32(35):3939\u20133947","journal-title":"J Clin Oncol"},{"issue":"5","key":"2193_CR31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13679","volume":"119","author":"D Tilki","year":"2017","unstructured":"Tilki\u00a0D, Preisser\u00a0F, Tennstedt\u00a0P et\u00a0al (2017) Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int 119(5):717\u2013723","journal-title":"BJU Int"},{"issue":"3","key":"2193_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/cncr.30373","volume":"123","author":"N Jegadeesh","year":"2017","unstructured":"Jegadeesh\u00a0N, Liu\u00a0Y, Zhang\u00a0C et\u00a0al (2017) The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. Cancer 123(3):512\u2013520","journal-title":"Cancer"},{"issue":"20","key":"2193_CR33","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1200\/JCO.21.02800","volume":"40","author":"D Tilki","year":"2022","unstructured":"Tilki\u00a0D, Chen\u00a0MH, Wu\u00a0J et\u00a0al (2022) Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J\u00a0Clin Oncol 40(20):2186\u20132192","journal-title":"J Clin Oncol"},{"issue":"1","key":"2193_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eururo.2017.10.009","volume":"74","author":"SJ Ramey","year":"2018","unstructured":"Ramey\u00a0SJ, Agrawal\u00a0S, Abramowitz\u00a0MC et\u00a0al (2018) Multi-institutional evaluation of elective nodal irradiation and\/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer. Eur Urol 74(1):99\u2013106","journal-title":"Eur Urol"},{"issue":"4","key":"2193_CR35","doi-asserted-by":"publisher","first-page":"e0215057","DOI":"10.1371\/journal.pone.0215057","volume":"14","author":"C Song","year":"2019","unstructured":"Song\u00a0C, Byun\u00a0SJ, Kim\u00a0YS et\u00a0al (2019) Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: a\u00a0propensity score matching analysis. PLoS ONE 14(4):e215057","journal-title":"PLoS ONE"},{"key":"2193_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fonc.2020.00312","volume":"10","author":"MJ Kucharczyk","year":"2020","unstructured":"Kucharczyk\u00a0MJ, Tsui\u00a0JMG, Khosrow-Khavar\u00a0F et\u00a0al (2020) Combined long-term androgen deprivation and pelvic radiotherapy in the post-operative management of pathologically defined high-risk prostate cancer patients: results of the prospective phase\u00a0II McGill 0913 study. Front Oncol 10:312","journal-title":"Front Oncol"},{"issue":"10338","key":"2193_CR37","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack\u00a0A, Karrison\u00a0TG, Balogh\u00a0AG et\u00a0al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase\u00a03\u00a0trial. Lancet 399(10338):1886\u20131901","journal-title":"Lancet"},{"issue":"2","key":"2193_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euo.2022.01.001","volume":"5","author":"D Meijer","year":"2022","unstructured":"Meijer\u00a0D, Eppinga\u00a0WSC, Mohede\u00a0RM et\u00a0al (2022) Prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol 5(2):146\u2013152","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"2193_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","volume":"49","author":"P Rogowski","year":"2022","unstructured":"Rogowski\u00a0P, Trapp\u00a0C, von Bestenbostel\u00a0R et\u00a0al (2022) Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 49(4):1417\u20131428","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2193_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06185-5","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou\u00a0N, Germanou\u00a0D, Strouthos\u00a0I et\u00a0al (2023) PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA \u3008\u202f0.2\u202fng\/ml. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-023-06185-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2193_CR41","doi-asserted-by":"publisher","first-page":"e2314748","DOI":"10.1001\/jamanetworkopen.2023.14748","volume":"6","author":"C Zamboglou","year":"2023","unstructured":"Zamboglou\u00a0C, Peeken\u00a0JC, Janbain\u00a0A et\u00a0al (2023) Development and validation of a\u00a0multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6(5):e2314748","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2193_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley\u00a0WU, Seiferheld\u00a0W, Lukka\u00a0HR et\u00a0al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N\u00a0Engl J Med 376(5):417\u2013428","journal-title":"N Engl J Med"},{"issue":"12","key":"2193_CR43","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie\u00a0C, Magn\u00e9\u00a0N, Burban-Provost\u00a0P et\u00a0al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU16): a\u00a0112-month follow-up of a\u00a0phase\u00a03, randomised trial. Lancet Oncol 20(12):1740\u20131749","journal-title":"Lancet Oncol"},{"issue":"10356","key":"2193_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(22)01440-4","volume":"400","author":"P Ghadjar","year":"2022","unstructured":"Ghadjar\u00a0P, Koerber\u00a0SA, H\u00f6lscher\u00a0T et\u00a0al (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):883\u2013884","journal-title":"Lancet"},{"issue":"10356","key":"2193_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(22)01488-X","volume":"400","author":"A Kahvecioglu","year":"2022","unstructured":"Kahvecioglu\u00a0A, Yilmaz\u00a0MT, Hurmuz\u00a0P (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):884\u2013885","journal-title":"Lancet"},{"issue":"10356","key":"2193_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0140-6736(22)01482-9","volume":"400","author":"F Turco","year":"2022","unstructured":"Turco\u00a0F, Gillessen\u00a0S, Bosetti\u00a0DG et\u00a0al (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):885","journal-title":"Lancet"},{"issue":"12","key":"2193_CR47","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00066-022-02001-5","volume":"198","author":"F Grabenbauer","year":"2022","unstructured":"Grabenbauer\u00a0F, Flentje\u00a0M (2022) Salvage prostate bed radiotherapy: co-irradiation of regional LNs and significance of ADT. Strahlenther Onkol 198(12):1119\u20131121","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"2193_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00066-018-1269-3","volume":"194","author":"P Ghadjar","year":"2018","unstructured":"Ghadjar\u00a0P, Aebersold\u00a0DM, Albrecht\u00a0C et\u00a0al (2018) Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol 194(7):619\u2013626","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"2193_CR49","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck\u00a0T, van den Bergh\u00a0RCN, Arfi\u00a0N et\u00a0al (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a\u00a0systematic review. Eur Urol 75(6):967\u2013987","journal-title":"Eur Urol"},{"issue":"5","key":"2193_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","volume":"6","author":"RT Dees","year":"2020","unstructured":"Dees\u00a0RT, Sun\u00a0Y, Jackson\u00a0WC et\u00a0al (2020) Association of presalvage radiotherapy PSA levels after prostatectomy with outomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol 6(5):735\u2013743","journal-title":"JAMA Oncol"},{"issue":"7","key":"2193_CR51","doi-asserted-by":"publisher","first-page":"S1427","DOI":"10.1016\/j.annonc.2022.08.064","volume":"33","author":"CC Parker","year":"2022","unstructured":"Parker\u00a0CC, Clarke\u00a0N, Cook\u00a0A et\u00a0al (2022) Duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial. Ann Oncol 33(7):S1427","journal-title":"Ann Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02193-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02193-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02193-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T17:02:55Z","timestamp":1708362175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02193-4"}},"subtitle":["Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)"],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2193"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02193-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.\u00a0Koerber, S.\u00a0H\u00f6cht, D.\u00a0Aebersold, C.\u00a0Albrecht, D.\u00a0Boehmer, U.\u00a0Ganswindt, N.-S.\u00a0Schmidt-Hegemann, T.\u00a0H\u00f6lscher, A.-C.\u00a0Mueller, P.\u00a0Niehoff, J.\u00a0C.\u00a0Peeken, M.\u00a0Pinkawa, B.\u00a0Polat, S.K.B.\u00a0Spohn, F.\u00a0Wolf, C.\u00a0Zamboglou, D.\u00a0Zips and T.\u00a0Wiegel declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}